The role of p27Kip1 in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells

Journal of the National Cancer Institute

Volumn 103, Issue 18, 2011, Pages 1403-1422

  Le, Xiao Feng ^a   Mao, Weiqun ^a   He, Guangan ^a   Claret, Francois Xavier ^a   Xia, Weiya ^a   Ahmed, Ahmed Ashour ^a   Hung, Mien Chie ^b   Siddik, Zahid H ^a   Bast, Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DASATINIB; PACLITAXEL; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LINE HEY; CELL STRAIN SKOV3; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-1; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RESEARCH DESIGN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SERINE; SRC-FAMILY KINASES; THIAZOLES; THREONINE; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053291558     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr280     Document Type: Article

References (63)

1. Bast RC Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415-428.
2. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3(6):755-766. (Pubitemid 34649705)
3. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5(suppl 6):S3-S6.
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665-667. (Pubitemid 9114288)
5. Guastalla JP, Pujade-Lauraine E, Weber B, et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol. 1998;9(1):37-43. (Pubitemid 28125762)
6. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 1998;16(8):2620-2624. (Pubitemid 28363024)
7. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16(4):1494-1497. (Pubitemid 28175771)
8. Oliverio G, Canuti D, Tononi A, et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. J Chemother. 1999;11(4):301-305. (Pubitemid 29382626)
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
10. Manning BD. Challenges and opportunities in defining the essential cancer kinome. Sci Signal. 2009;2(63):pe15.
11. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta. 2004;1697(1-2):243-257. (Pubitemid 38326776)
12. Vieth M, Erickson J, Wang J, et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem. 2009;52(20):6456-6466.
13. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000;6(1):260-270. (Pubitemid 30065001)
14. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010;116(21):4980-4990.
15. Le XF, Lammayot A, Gold D, et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 2005;280(3):2092-2104.
16. Le XF, Vallian S, Mu ZM, Hung MC, Chang KS. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene. 1998;16(14):1839-1849. (Pubitemid 28197403)
17. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191.
18. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 1993;262(5142):2050-2054. (Pubitemid 24041887)
19. Le XF, Claret FX, Lammayot A, et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem. 2003;278(26):23441-23450. (Pubitemid 36830161)
20. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401. (Pubitemid 38938156)
21. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65(20):9185-9189. (Pubitemid 41507982)
22. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14(2):352-359. (Pubitemid 351226100)
23. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27-42.
24. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular defnition. Oncogene. 2004;23(16):2825-2837. (Pubitemid 38638845)
25. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183(1):10-17. (Pubitemid 30130220)
26. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 1996;16(10):5546-5556. (Pubitemid 26315074)
27. Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science. 1999;286(5448):2358-2361. (Pubitemid 30016901)
28. Nakayama K, Nagahama H, Minamishima YA, et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 2004;6(5):661-672. (Pubitemid 38579350)
29. Gabellini C, Pucci B, Valdivieso P, et al. p27kip1 overexpression promotes paclitaxel-induced apoptosis in pRb-defective SaOs-2 cells. J Cell Biochem. 2006;98(6):1645-1652. (Pubitemid 44141866)
30. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269(5224):682-685.
31. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8(10):1136- 1144. (Pubitemid 35175969)
32. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145-1152. (Pubitemid 35175970)
33. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153-1160. (Pubitemid 35175971)
34. Boehm M, Yoshimoto T, Crook MF, et al. A growth factor-dependent nuclear kinase phosphorylates p27 (Kip1) and regulates cell cycle progression. EMBO J. 2002;21(13):3390-3401. (Pubitemid 34760571)
35. Grimmler M, Wang Y, Mund T, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007;128(2):269-280. (Pubitemid 46123508)
36. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128(2):281-294. (Pubitemid 46123510)
37. Le XF, Pruefer F, Bast RC Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. 2005;4(1):87-95. (Pubitemid 41038933)
38. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther. 2005;4(2):217-224. (Pubitemid 40340201)
39. George JA, Chen T, Taylor CC. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005;65(22):10381-10388. (Pubitemid 41743731)
40. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006;66(17):8633- 8639. (Pubitemid 44449178)
41. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002;21(41):6249-6254.
42. Kubota T, Uemura Y, Kobayashi M, Taguchi H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res. 2003;23(5 A):4039-4046. (Pubitemid 37474362)
43. Kim JW, Kim HP, Im SA, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008;272(2):296-306.
44. Dietrich CS III, Greenberg VL, DeSimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol. 2010;116(1):126-130.
45. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. (Pubitemid 32222155)
46. Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood fow. Clin Cancer Res. 2000;6(4):1498-1507. (Pubitemid 30226239)
47. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001;7(8):2168-2181. (Pubitemid 32751613)
48. Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene. 2000;19(20):2423-2429. (Pubitemid 30323475)
49. Chen W, Yu YL, Lee SF, et al. CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal. Mol Cell Biol. 2001;21(14):4636-4646. (Pubitemid 32588246)
50. Heckman CA, Mehew JW, Boxer LM. NF-κB activates Bcl-2 expression in t (14;18) lymphoma cells. Oncogene. 2002;21(24):3898-3908. (Pubitemid 34620858)
51. Hitomi M, Yang K, Guo Y, Fretthold J, Harwalkar J, Stacey DW. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle. 2006;5(19):2281-2289. (Pubitemid 44546566)
52. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-1512. (Pubitemid 29297917)
53. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 2007;6(1):70-74. (Pubitemid 46178022)
54. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol. 2008;182(4):623-629.
55. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle. 2009;8(6):876-888.
56. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3(3):193-203. (Pubitemid 36565761)
57. Riffell JL, Zimmerman C, Khong A, McHardy LM, Roberge M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle. 2009;8(18):3025-3038.
58. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-7186. (Pubitemid 44974520)
59. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/striple-negative" brea"t cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105(3):319-326. (Pubitemid 47596452)
60. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting Sensitivity in Solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67(5):2226-2238. (Pubitemid 46424242)
61. Konecny GE, Glas R, Dering J, et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer. 2009;101(10):1699-1708.
62. Wang XD, Reeves K, Luo FR, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol. 2007;8(11):R255.
63. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006;5(12):3014-3022. (Pubitemid 46092042)